Centre Hospitalier Universitaire de Besançon

Running trials

• Not yet recruiting

  Safety and Efficacy of a STOPping Strategy Versus Classical Maintenance Dose of JAK Inhibitors in Deep Remission Patients With Ulcerative Colitis

  NCT07718529· Phase 4· Assistance Publique Hopitaux De Marseille· Source

• Not yet recruiting

  Analysis of histological risk factors and biomarkers in paediatric retinoblastoma

  2024-515962-15-00· Phase 2· Institut Curie· Source

• Not yet recruiting

  Prognostic and Predictive Factors in Childhood Soft Tissue Sarcomas

  NCT07924384· Institut Curie· Source

• Not yet recruiting

  FILOCLL017 - NEVOTAL : Nemtabrutinib in addition to Venetoclax-Obinutuzumab in chronic lymphocytic leukemia (CLL) / small lymphocytic leukemia (SLL) patients with TP53 ALterations

  2026-525763-40-00· Phase 2· French Innovative Leukemia Organization (F.I.L.O.).· Source

• Not yet recruiting

  FirST Lines of Biologics in pAtients With ulceRaTivE Colitis: a Randomised Controlled Trial

  NCT07576452· Phase 4· University Hospital, Clermont-Ferrand· Source

• Not yet recruiting

  Efficacy of Upadacitinib Re-induction Therapy in Patients With Ulcerative Colitis Who Lost Response to 30 mg Maintenance Dose

  NCT07700446· Phase 4· Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives· Source

• Recruiting

  Predicting Response to Anti-PD-1/PD-L1 Immunotherapy by Plasma Extracellular Vesicle Analysis

  NCT07376512· Centre Georges Francois Leclerc· Source

• Recruiting

  A clinical trial to assess the efficacy and safety of ontunisertib compared to placebo in patients with fibrostenosing Crohn’s disease

  2026-525197-19-00· Phase 2· Agomab Spain S.L.U.· Source

• Recruiting

  Phase 3 Study of Azenosertib Versus Chemotherapy in Platinum-Resistant Ovarian Cancers Positive for Cyclin E1 Protein Expression

  2025-524641-27-00· Phase 3· K-Group Beta Inc.· Source

• Not yet recruiting

  Comparative Study of Two Vaccination Schedules for the Subunit Herpes Zoster Vaccine in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disease Patients Treated With Anti-CD20 Therapy: an Open-label Randomised Controlled Trial

  NCT07818356· Phase 4· University Hospital, Toulouse· Source

• Not yet recruiting

  Evaluation of the Efficacy and Safety of Bimekizumab (BZK) or Adalimumab (ADA) in the Treatment of Anterior Chest Wall Pain Associated With Active Axial Spondyloarthritis Refractory to NSAIDs With Hypothesis of Superiority of Bimekizumab

  NCT07836283· Phase 3· University Hospital, Rouen· Source

• Recruiting

  Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse

  NCT07871864· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source

• Recruiting

  Phase 3 Trial of Tarlatamab (SC vs IV) In Extensive-Stage Small Cell Lung Cancer After Platinum based First-line Chemotherapy (DeLLphi-315)

  2026-525489-23-00· Phase 3· Amgen Inc.· Source

• Recruiting

  Characterization of Colorectal Dysplasic Lesions and Stratification of Their Evolving Risk in Inflammatory Bowel Disease Patients: a Prospective, Observational and Multicenter Study

  NCT07719426· Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives· Source

• Not yet recruiting

  Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease

  NCT07420439· Phase 2· Intergroupe Francophone de Cancerologie Thoracique· Source

• Recruiting

  A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum

  NCT07811193· Phase 2· Vividion Therapeutics, Inc.· Source

• Not yet recruiting

  Superior Mesenteric Artery First Versus Standard Approach in Pancreaticoduodenectomy

  NCT07547033· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)

  NCT07476729· Phase 3· Charite University, Berlin, Germany· Source

• Not yet recruiting

  Fixed Duration Treatment With Combined Pirtobrutinib and Short Course Immuno-chemotherapy in Fit Patients With Previously Untreated Symptomatic Chronic Lymphocytic Leukemia (CLL).

  NCT07624799· Phase 2· French Innovative Leukemia Organisation· Source

• Not yet recruiting

  Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy.

  NCT07463768· Phase 2· French Innovative Leukemia Organisation· Source

• Recruiting

  Fight Osteosarcoma Through European Research evolving study platform from diagnosis to relapse (FOSTER evolving study platform)

  2023-505575-69-01· Phase 3· Institut Gustave Roussy· Source

• Recruiting

  Personalizing chemotherapy selection after surgery for patients with stage III colorectal cancer using a blood test

  2025-521045-24-00· Phase 3· Unicancer· Source

• Recruiting

  PRODIGE 104 – NEOPREDICT A multicenter phase II trial using transcriptomic signatures to personalize neoadjuvant chemotherapy for patients with resectable borderline pancreatic adenocarcinoma.

  2024-519753-11-00· Phase 2· Fondation Franc.Cancerologie Digestive· Source

• Recruiting

  Efficacy of an Anti-TSLP Monoclonal Antibody in the Management of Chronic Bronchial Disease Induced by Bronchiolitis Obliterans Syndrome in Allogeneic Hematopoietic Stem Cells Transplantation Recipients

  NCT07771855· Phase 2· Hopital Foch· Source

• Recruiting

  Optimal Care With Guselkumab in Crohn's Disease / OPTIM Study A Prospective Open Label Interventional, Multicenter Study

  NCT07616687· Phase 4· Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives· Source

• Recruiting

  Genotype/Phenotype Correlation of MORC2 Mutations

  NCT07038239· Hospices Civils de Lyon· Source

• Not yet recruiting

  Intravenous Thrombolysis With Tenecteplase Plus Thrombectomy Versus Thrombectomy Alone In Patients With A Large Ischemic Stroke: A Multicenter Randomized Controlled Trial (IVT-ALL-IN)

  NCT07603440· Phase 3· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  French Minds Cohort: a French Longitudinal and Multimodal Cohort of Patients With Major Mood Disorders, Psychotic Disorders, Autism Spectrum Disorders, and Healthy Controls

  NCT07881016· Fondation FondaMental· Source

• Recruiting

  Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

  NCT07562152· Phase 3· Immuneering Corporation· Source

• Not yet recruiting

  A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APPROACH. ALL-TARGET TRIAL

  2024-516570-30-00· Phase 2· Centre Hospitalier De Versailles· Source

• Not yet recruiting

  Developmental and Epileptic Encephalopathies Diagnosed Via Long-read Genome Sequencing

  NCT07396883· University Hospital, Strasbourg, France· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07577856· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

  NCT07577843· Phase 3· Janssen Research & Development, LLC· Source

• Not yet recruiting

  Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis

  NCT07018206· Phase 4· CARE ARTHRITIS LTD.· Source

• Recruiting

  A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis

  2025-521546-23-00· Phase 3· Novartis Pharma AG· Source

• Recruiting

  MATRIX-IPC 2022-029 A phase I/II study evaluating Tuvusertib (M1774), an ATR Inhibitor, in combination with fulvestrant in hormone receptors-positive and HER2-negative, advanced breast cancers, resistant to CDK4/6 inhibitor plus aromatase inhibitor-based endocrine treatment and with homologous recombination deficiency, oncogenic driver activation and/or other molecular alterations associated with replication stress (RS)

  NCT05986071· Phase 1/2· Institut Paoli-Calmettes· Source

• Recruiting

  Trial assessing fianlimab plus cemiplimab plus chemotherapy or cemiplimab plus chemotherapy in patients with pleural mesothelioma

  2024-519208-29-00· Phase 2· Intergroupe Francophone De Cancerologie Thoracique· Source

• Recruiting

  Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma

  NCT07234058· Phase 2· Intergroupe Francophone de Cancerologie Thoracique· Source

• Recruiting

  A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

  NCT07067463· Phase 3· Zenas BioPharma (USA), LLC· Source

• Recruiting

  A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

  NCT07299019· Phase 3· Zenas BioPharma (USA), LLC· Source

• Recruiting

  Omnipod-5 A French Prospective Multicentric Study in Real World (Optimal-B)

  NCT07317102· Insulet Corporation· Source

• Recruiting

  Safety and Efficacy of Very Short DAPT in Older Patients Undergoing PCI

  NCT07164859· Phase 3· Vincent ROULE· Source

• Not yet recruiting

  Sustained-release oral morphine to alleviate persistent dyspnea in patients with chronic respiratory insufficiency due to amyotrophic lateral sclerosis outside the administration of ventilatory assistance: prospective multicenter randomized, placebo-controlled study, parallel arms (OPIDYS-ALS).

  2025-522546-52-00· Phase 3· Assistance Publique Hopitaux De Paris· Source

• Recruiting

  Pancreatic cancer first-line NALIRIFOX optimization with 5-FU maintenance and role of antibiotics and microbiota exploration in second-line treatment – A non-comparative, randomized phase II PANORAMIX GERCOR G-116 PRODIGE 105 study

  2024-517766-41-00· Phase 2· Association Gercor· Source

• Recruiting

  Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)

  NCT06937905· Phase 3· Intergroupe Francophone de Cancerologie Thoracique· Source

• Not yet recruiting

  Interest of Adaptated Physical Activity (APA) on the K Recovery Constant, Reflecting the Rate of Muscle Oxygenation Recovery in Menopausal Women Suffering From Depression

  NCT07417709· Centre Hospitalier Universitaire de Besancon· Source

• Recruiting

  Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT07222566· Phase 3· Pfizer· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

  NCT07221357· Phase 2/3· Bristol-Myers Squibb· Source

• Not yet recruiting

  Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer

  NCT07150403· Phase 2· Federation Francophone de Cancerologie Digestive· Source

• Recruiting

  A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  NCT07174336· Phase 3· Eli Lilly and Company· Source

Showing 50 of 288.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers24 recruiting
• Colorectal cancer22 recruiting
• Pancreatic cancer14 recruiting
• Crohn's disease11 recruiting
• Lung cancer11 recruiting
• Metastatic breast cancer10 recruiting
• Sarcoma10 recruiting
• Ovarian cancer9 recruiting
• Endometrial cancer8 recruiting
• Liver and biliary tract cancer8 recruiting
• Acute myeloid leukaemia7 recruiting
• Multiple sclerosis7 recruiting
• Ulcerative colitis7 recruiting
• Head and neck cancer6 recruiting
• Heart failure6 recruiting
• Melanoma5 recruiting
• Neuroendocrine tumours5 recruiting
• Ankylosing spondylitis4 recruiting
• Bladder cancer4 recruiting
• Gastric and oesophageal cancer4 recruiting
• Kidney cancer4 recruiting
• Multiple myeloma4 recruiting
• Stroke4 recruiting
• Acute lymphoblastic leukaemia3 recruiting
• Brain aneurysm3 recruiting
• Chronic lymphocytic leukaemia3 recruiting
• Liver cirrhosis3 recruiting
• Neuroblastoma3 recruiting
• Prostate cancer3 recruiting
• Psoriasis3 recruiting
• Rheumatoid arthritis3 recruiting
• Aplastic anaemia2 recruiting
• Atopic dermatitis (eczema)2 recruiting
• Atrial fibrillation2 recruiting
• Epilepsy2 recruiting
• Fatty liver disease (MASLD/MASH)2 recruiting
• Follicular lymphoma2 recruiting
• Hidradenitis suppurativa2 recruiting
• High blood pressure2 recruiting
• HIV2 recruiting
• IgA nephropathy2 recruiting
• Mesothelioma2 recruiting
• Neuromyelitis optica (NMOSD)2 recruiting
• Osteoarthritis2 recruiting
• Parkinson disease2 recruiting
• Psoriatic arthritis2 recruiting
• ALS (motor neurone disease)1 recruiting
• Aortic stenosis1 recruiting
• Cervical cancer1 recruiting
• Charcot-Marie-Tooth disease1 recruiting
• Chronic kidney disease1 recruiting
• Coronary artery disease1 recruiting
• Depression1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Essential tremor1 recruiting
• Glioblastoma1 recruiting
• Haemophilia1 recruiting
• Hearing loss1 recruiting
• Hepatitis C1 recruiting
• Hodgkin lymphoma1 recruiting
• Lupus (SLE)1 recruiting
• Mantle cell lymphoma1 recruiting
• Triple-negative breast cancer1 recruiting
• Type 1 diabetes1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Completed

  A multicentre, randomised, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of BP1.4979 in adult patients with essential tremor

  2024-517987-46-00· Phase 2· Bioprojet Pharma· Source

• Active, not recruiting

  A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis

  NCT06863961· Phase 2· Hoffmann-La Roche· Source

• Completed

  A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia

  2024-511057-22-00· Phase 3· Janssen Cilag International· Source

• Terminated

  Use of a Treated, Devitalized and Sterile Umbilical Cord Amniotic Membrane in the Treatment of PIP Joint Osteoarthritis

  NCT06034262· Phase 2· TBF Genie Tissulaire· Source

• Completed

  Efficacy Assessment of Lenvatinib Associated with Pembrolizumab in Metastatic Endometrial Cancer: a French Multicentric Retrospective Early Access Program-based Study

  NCT06599463· ARCAGY/ GINECO GROUP· Source

• Completed

  Reperfusion with P2Y12 inhibitors in addition to mechanical thrombectomy for perfusion imaging selected acute stroke patients : a multicentric randomized controlled trial

  NCT04667078· Phase 4· Fondation A De Rothschild· Source

• Completed

  A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments

  NCT06323928· Phase 2· H. Lundbeck A/S· Source

• Completed

  Evaluation by a Vineland II Scale of Long-term Development of Children With Pyridoxine Dependent Epilepsy

  NCT06054347· University Hospital, Angers· Source

• Completed

  Validation of KELIM as a Predictive/Prognostic Factor for Maintenance Treatment With iPARP in First-Line Ovarian Cancer

  NCT06660147· ARCAGY/ GINECO GROUP· Source

• Completed

  A Study of LY8888AX in Participants Using a Connected Insulin Management Platform

  NCT05893797· Eli Lilly and Company· Source

• Terminated

  Post Intensive Care Unit Atrial Fibrillation

  NCT05860894· Centre Hospitalier Universitaire de Besancon· Source

• Completed

  Preferences of Patients Treated With Oral Cancer Drugs and Informal Caregivers for Pharmaceutical Consultation in Hospital

  NCT05970471· Centre Hospitalier Universitaire de Besancon· Source

• Completed

  Impact of ECMO Cannula Chlorhexidine-impregnated Dressings to Decrease Extracorporeal Membrane Oxygenation-cannula Related Infection Rate

  NCT05750576· Assistance Publique - Hôpitaux de Paris· Source

• Terminated

  EO4010 in Previously Treated Metastatic Colorectal Carcinoma

  NCT05589597· Phase 1/2· Enterome· Source

• Completed

  A clinical trial to investigate EO4010, a novel cancer vaccine therapy, with an immune checkpoint blocker, in patients with previously treated metastatic colorectal carcinoma.

  2023-509509-62-00· Phase 1/2· Enterome· Source

• Completed

  A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

  NCT05805501· Phase 2· Hoffmann-La Roche· Source

• Terminated

  CO2 Removal in Severe Acute exacerbatIons of Chronic Obstructive Lung Diseases

  NCT05546606· Assistance Publique - Hôpitaux de Paris· Source

• Completed

  A Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate in Children With Refractory or Recurrent Neuroblastoma Expressing Somatostatin Receptors.

  NCT03966651· Phase 1· Institut Claudius Regaud· Source

• Completed

  Treatment of Metastatic Melanoma with Lenvatinib + Anti-PD1

  NCT06586580· Centre Hospitalier Universitaire de Besancon· Source

• Completed

  Dupilumab Step-down Strategy to Maintain Remission in Adult and Adolescents Patients With Atopic Dermatitis

  NCT05642208· Phase 4· Nantes University Hospital· Source

• Completed

  An Observational Study to Assess Change in Disease Activity and Treatment Patterns of Upadacitinib When Given Alone or Co-Administered With Methotrexate in Adult Participants With Active Psoriatic Arthritis

  NCT05616871· AbbVie· Source

• Completed

  Low-Protein Diet With Low-Protein Foods Versus a LPD Without LP Foods in Patients With Chronic Kidney Disease (CKD)

  NCT05489120· Dr. Schär AG / SPA· Source

• Completed

  Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab (MESO-IMMUNE)

  NCT05308966· Groupe Francais De Pneumo-Cancerologie· Source

• Completed

  Objective and Perceived Health Status of Elderly People With Moderate or Severe Haemophilia in France: an Ancillary Study of the FranceCoag Registry

  NCT05218772· Assistance Publique Hopitaux De Marseille· Source

• Completed

  A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)

  NCT05259033· Phase 3· Novo Nordisk A/S· Source

• Terminated

  SafeHeal Colovac Colorectal Anastomosis Protection Device Evaluation (SAFE-2) Pivotal Study

  NCT05010850· SafeHeal Inc· Source

• Completed

  Normoxemic Versus Hyperoxemic Extracorporeal Oxygenation in Patients Supported by Veino-arterial ECMO for Cardiogenic Shock

  NCT04990349· Phase 3· Centre Hospitalier Universitaire de Besancon· Source

• Terminated

  GEN1047 for Solid Tumors - First in Human (FIH) Trial

  NCT05180474· Phase 1/2· Genmab· Source

• Active, not recruiting

  OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC

  NCT04713514· Phase 2· ARCAGY/ GINECO GROUP· Source

• Terminated

  Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).

  NCT04949256· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Coronary Flow and Myocardial Viability: the FloVITA Study

  NCT04818918· Centre Hospitalier Universitaire de Besancon· Source

• Completed

  Effectiveness of Treatment With Tofacitinib in Patients With Psoriatic Arthritis in Routine Clinical Practice

  NCT04517669· Pfizer· Source

• Completed

  Setting a Benchmark for Resource Utilization and Quality of Care in Patients Undergoing TAVI in Europe

  NCT04579445· Institut für Pharmakologie und Präventive Medizin· Source

• Completed

  BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS

  NCT04827719· Phase 2· Groupe Francophone des Myelodysplasies· Source

• Terminated

  Medico-economic Evaluation of Therapeutic Adaptation Guided by the Soluble Suppression of Tumorigenicity 2 (sST-2) Biomarker in the Management of Patients With Acute Heart Failure

  NCT04554277· University Hospital, Montpellier· Source

• Completed

  Multicentric Prospective Study to Screen Inborn Errors of Metabolism in Non-immune Hydrops (NIH) Fetalis by Massively Parallel Sequencing

  NCT04308603· Hospices Civils de Lyon· Source

• Completed

  Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer

  NCT04744831· Phase 2· Daiichi Sankyo· Source

• Active, not recruiting

  A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation

  NCT04625270· Phase 2· Verastem, Inc.· Source

• Completed

  Tofacitinib in Adult Patients With Moderate to Severe Ulcerative Colitis

  NCT04424303· Pfizer· Source

• Completed

  A Study of Oral Upadacitinib Tablets to Assess Treatment Patterns, Achievement of Treatment Targets and Maintenance of Response in Adult Participants With Moderate to Severe Rheumatoid Arthritis

  NCT04497597· AbbVie· Source

• Completed

  Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer

  NCT04534218· Phase 2· Centre Hospitalier Universitaire de Besancon· Source

• Completed

  Immunotherapy in Patient With Poor General Condition

  NCT04108026· Phase 2· Intergroupe Francophone de Cancerologie Thoracique· Source

• Completed

  A Phase 1, Open-Label, Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Patients with Advanced Solid Tumors and Subsequent Expansion Cohorts

  2024-518506-41-00· Phase 1/2· Promontory Therapeutics Inc.· Source

• Terminated

  Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months

  NCT04826198· Phase 1/2· Gustave Roussy, Cancer Campus, Grand Paris· Source

• Completed

  Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung Cancer

  NCT04263051· Phase 2· Centre Hospitalier Universitaire de Besancon· Source

• Completed

  Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)

  NCT04456699· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy versus systemic chemotherapy alone as 1st-line treatment of Malignant Peritoneal Mesothelioma

  NCT03875144· Phase 2· Institut Regional Du Cancer De Montpellier· Source

• Completed

  A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer

  NCT04322539· Phase 3· Hutchison Medipharma Limited· Source

• Completed

  Does OCT Optimise Results of Stenting on the Left Main Stem

  NCT04391413· Centre Hospitalier Universitaire de Besancon· Source

• Completed

  Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer

  NCT04111705· Phase 2· Intergroupe Francophone de Cancerologie Thoracique· Source

Showing 50 of 100.

Conditions

Diseases this institution publishes on or runs trials for.

• Ankylosing spondylitis12 works · 5 trials
• Aplastic anaemia3 works · 2 trials